Literature DB >> 9860186

Interferon induction in turkeys by oral administration of the imidazoquinolinamine S-28828 and modulation of the pathogenesis of Escherichia coli.

S Rautenschlein1, R L Miller, J M Sharma.   

Abstract

A synthetic imidazoquinolinamine, S-28828, has been shown to be an effective antiviral and antitumor agent in mammals. This immune modifier induces a number of cytokines such as interferons, tumor necrosis factor-alpha, interleukins and granulocyte-macrophage colony-stimulating factors in mammals. We showed that when turkeys were given S-28828 orally, high serum titers of IFN were induced in a dose-dependent manner. Turkeys, once stimulated by S-28828, became refractory to IFN production by repeated stimulation. S-28828 induced spleen, bone marrow and peripheral leukocytes to produce IFN in vitro. Splenic adherent cells were the main producers of IFN after in vitro stimulation. S-28828-induced IFN was identified as type I IFN that was pH-resistant but heat-labile. We examined the effect of a high dose (100 mg kg(-1) body weight) of S-28828 on the pathogenesis of E. coli in turkeys. Treatment with S-28828 increased mortality in infected birds and impaired E. coli clearance from the liver. The enhancement of the pathogenicity of E. coli by S-28828 may have been due to the massive release of cytokines inducing a shock-like syndrome in infected turkeys.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9860186     DOI: 10.1016/s0165-2427(98)00197-4

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  1 in total

1.  Pathological Alterations in Respiratory System During Co-infection with Low Pathogenic Avian Influenza Virus (H9N2) and Escherichia Coli in Broiler Chickens.

Authors:  Shahid Jaleel; Muhammad Younus; Asif Idrees; Muhammad Arshad; Aman Ullah Khan; Syed Ehtisham-Ul-Haque; Muhammad Irfan Zaheer; Muhammad Tanweer; Farhan Towakal; Muhammad Yasin Tipu; Muhammad Luqman Sohail; Sajid Umar
Journal:  J Vet Res       Date:  2017-09-19       Impact factor: 1.744

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.